Table 1.

Therapeutic compounds that show significant subtype specificity

CompoundTargetBasal vs. claudin-low vs. luminalBasal and claudin-low vs. luminalERBB2AMP vs. not ERBB2AMPSubtype specificity
LapatinibEGFR, ERBB27.23E-023.34E-022.26E-06Luminal/ERBB2AMP
Sigma AKT1-2 inh.AKT1, AKT21.17E-032.63E-041.29E-01Luminal
GSK2126458PIK3C A/B/D/G1.27E-031.27E-038.67E-02Luminal/ERBB2AMP
GefitinibEGFR4.89E-013.35E-014.14E-03ERBB2AMP
BIBW 2992EGFR, ERBB26.93E-018.08E-016.39E-03ERBB2AMP
GSK2119563PIK3CA2.85E-028.11E-038.67E-02Luminal/ERBB2AMP
RapamycinMTOR1.45E-028.11E-033.84E-01Luminal
AG1478EGFR9.34E-019.34E-012.60E-02ERBB2AMP
EtoposideTOP2A3.34E-025.13E-028.89E-01Claudin-low
LBH589HDAC5.14E-023.34E-023.22E-01Luminal
VorinostatHDAC7.23E-023.34E-026.89E-01Luminal
CisplatinDNA cross-linker8.45E-024.31E-028.52E-01Basal/Claudin-low
FascaplysinCDK44.83E-024.31E-023.70E-01Luminal
DocetaxelTUBB1, BCL28.67E-024.83E-028.44E-01Basal/Claudin-low
GSK1070916AURK B/C5.13E-024.83E-024.82E-01Claudin-low
PD173074FGFR35.13E-023.68E-015.06E-01Claudin-low
Trichostatin AHDAC1.22E-015.13E-027.10E-01Luminal
TriciribineAKT, ZNF2178.67E-025.91E-023.56E-01Luminal
CGC-11047Polyamine analog6.51E-021.25E-018.08E-01Basal
TemsirolimusMTOR1.64E-017.25E-021.29E-01Luminal
VX-680AURK A/B/C2.95E-014.02E-017.77E-02not ERBB2AMP
17-AAGHSP90AA11.83E-011.10E-018.67E-02ERBB2AMP
ErlotinibEGFR9.48E-022.83E-012.33E-01Basal
  • Each column represents q-values for one ANOVA. Compounds are ranked by the minimum q-value achieved across the three tests. BCL2, B-cell CLL/lymphoma 2; CDK4, cyclin-dependent kinase 4; HDAC, histone deacetylase; MTOR, mechanistic target of rapamycin; TOP2A, topoisomerase (DNA) II alpha 170kDa; TUBB1, tubulin β1; ZNF217, zinc finger protein 217.